lactobionic acid has been researched along with fluorouracil in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hassanzadeh, F; Khadem, M; Sadeghi, H; Varshosaz, J | 1 |
| Gao, X; Ji, Y; Jian, X; Li, Z; Liu, Z; Ni, W; Sun, S; Wu, L | 1 |
2 other study(ies) available for lactobionic acid and fluorouracil
| Article | Year |
|---|---|
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Topics: Acetone; Amines; Antineoplastic Agents; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Delayed-Action Preparations; Disaccharides; Drug Carriers; Drug Delivery Systems; Flow Cytometry; Fluorouracil; Galactose; Glycerides; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Spectroscopy; Nanoparticles; Oleic Acid; Particle Size; Polysorbates; Spectroscopy, Fourier Transform Infrared; Surface Properties; Tetrazolium Salts; Thiazoles; Toxicity Tests | 2012 |
Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biotin; Carcinoma, Hepatocellular; Curcumin; Disaccharides; Drug Carriers; Drug Liberation; Drug Synergism; Fluorouracil; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Nanoparticles; Polyethylene Glycols; Polyglactin 910; Tissue Distribution; Xenograft Model Antitumor Assays | 2019 |